Table 1.
Characteristics of the study participants at entry
| Characteristics | Total (n=40) | Efavirenz group (n=20) | Nevirapine group (n=20) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 31.0 (29.0–34.0) | 31.0 (28.3–34.0) | 32.5 (31.0–35.8) | ||||||
| Weight (kg) | 59.0 (53.0–68.0) | 59.5 (52.3–63.8) | 59.5 (54.3–69.8) | ||||||
| CD4 count (cells/mm3) | 579.0 (464.0–731.0) | 556.5 (477.3–663.5) | 626.0 (399.8–857.3) | ||||||
| Albumin concentration at baseline (g/L) | 43.7 (41.5–46.5) | 43.3 (40.7–45.1) | 43.1 (41.8–45.6) | ||||||
| SHBG at baseline (nmol/L) | 105.0 (82.3–136.0) | 100.0 (79.4–125.9) | 100.0 (100.0–125.9) | ||||||
| Genotype frequencies | |||||||||
| CYP2B6 516G>T (rs3745274) (%) | GG | GT | TT | GG | GT | TT | GG | GT | TT |
| 43 | 55 | 2 | 40 | 55 | 5 | 45 | 55 | 0 | |
| CYP2B6 983T>C (rs28399499) (%) | TT | CT | CC | TT | CT | CC | TT | CT | CC |
| 80 | 18 | 2 | 85 | 15 | 0 | 75 | 20 | 5 | |
| CYP2B6 15582C>T (rs4803419) (%) | CC | CT | TT | CC | CT | TT | CC | CT | TT |
| 28 | 70 | 2 | 25 | 75 | 0 | 30 | 65 | 5 | |
| CYP2A6*9B 1836G>T (rs8192726) (%) | GG | GT | TT | GG | GT | TT | GG | GT | TT |
| 82 | 18 | 0 | 80 | 20 | 0 | 75 | 25 | 0 | |
| CYP2A6 48A>C (rs28399433) (%) | AA | AC | CC | AA | AC | CC | AA | AC | CC |
| 78 | 22 | 0 | 75 | 25 | 0 | 70 | 30 | 0 | |
| NR1I2 63396C>T (rs2472677) (%) | CC | CT | TT | CC | CT | TT | CC | CT | TT |
| 63 | 30 | 7 | 65 | 30 | 5 | 60 | 30 | 10 | |
| NR1I3 540C>T (rs2307424) (%) | CC | CT | TT | CC | CT | TT | CC | CT | TT |
| 25 | 75 | 0 | 30 | 70 | 0 | 20 | 80 | 0 | |
| NR1I3 1089T>C (rs3003596) (%) | TT | CT | CC | TT | CT | CC | TT | CT | CC |
| 35 | 55 | 10 | 30 | 60 | 10 | 40 | 50 | 10 | |
Values shown as median (interquartile range) and percentage of population.